But not Eli Lilly.

The Indianapolis-based drugmaker—one of the largest producers of insulin—has been under fire from consumer advocates for jacking up prices on its lifesaving diabetes medication. And the company has chosen not to follow the California law, which requires it not only to disclose but also to justify significant price hikes to drug purchasers.